Corporate Executive Summary Dec 2020

Breakthrough in Cancer Treatment

ViDAC Pharma is a private clinical stage biopharmaceutical company developing first-in-class anti-cancer drugs.

ViDAC's innovations target cancer cells overexpressed Hexokinase 2 metabolic checkpoint (HK2) to selectively kill cancer cells without affecting surrounding normal tissue. ViDAC's drugs intervene in the cancer cells' nutrition, triggering dormant self-death mechanism (i.e., the apoptosis) thus reducing immune depression in tumor's environment while stimulating anti-tumor immune response in selected cancer cells only.



Lead drug: topical *tuvatexib* (*VDA-1102)* presents highest safety and selective efficacy in patients with Actinic Keratosis (AK) as demonstrated in a Phase 2b clinical trial (2019) and ready for Phase 2 in Cutaneous T Cell Lymphoma (CTCL).

Market

CTCL represents an unmet medical need of $900M worldwide equally divided between USA, Europe and Asia Pacific area. It is classified by FDA as Rare disease commending a fast track regulatory pathway. Global trends such as aging population, global warming and sun exposure in developed and emerging countries contributes to further grow ViDAC Pharma's total available market in the coming years.
Today, over 200 million Non-Melanoma Skin Cancer (NMSC) patients worldwide face inadequate treatment options to treat their debilitating recurring and even life-threatening diseases. Market opportunity includes more than $500 Million annual sales for first indication and more than $2 Billion annual sales across all indications for non-surgical removal of the tumors.

Lead Products: VDA-1102 for Non-Melanoma Skin Cancer and CTCL

ViDAC's pipeline includes several first-in-class potential drug candidates for a variety of indications.

VDA-1102 is a very potent, highly selective anti-cancer drug applied topically on skin to treat Actinic Keratosis (AK) recurring disease with incidence rate increasing with age as a primary indication. VDA-1102's mechanism of action, high efficacy and specificity towards cancer cells, position it as a high potential anti-cancer product for large range of NMSC such as CTCL, Squamous Cell Carcinoma (SCC) and Basal Cell

Contact Information:
Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com

Carcinoma (BCC). Unlike existing drugs generating severe side effects and pain, VDA-1102 is a first-in-class drug that treats NMSC without adversely affecting the surrounding healthy skin. Because of its unique characteristics and benefits, VDA-1102 is to become the drug of choice for first-line non-surgical treatment in a wide range of NMSC indications.

Recent data showing the potential of the drug for the treatment of CTCL and the fact that the Phase 1 and 2 made on AK showed exceptionally rare adverse effect, is the regulatory basis for going directly into a Phase 2 which begun (Dec 2020) on this extremely painful disease which lacks adequate medical treatment. Because of its classification, Phase 2 will comprise 20-30 patients and it is expected that phase 3 will demand as few as 100-150 patients. Helsinki Committee of Beilinson Hospital already authorized the Phase 2 under the supervision of Prof. Emilia Hodak one of the world KOL on this disease.

Business Opportunity

While the post Corona COVID19 might delay for a while completion of this phase 2 and 3 for AK due to the present reluctance of aged population to participate in clinical trials for a skin disease, it offers a rare opportunity to complete a Phase 2 for CTCL which is a more critical disease, for which patients are ready to try alternative treatments which might relieve them from the pain, look and itching accompanying CTCL.

Following further in-depth analysis of VDA-1102 Phase 2 results (2019), the management team discovered an unmatched success rate treatment for a selective population. The team decided to conduct an additional re-formulated complementary Phase 2b focused on safe permeability enhancer to test this population in parallel with the present formulation allowing targeted claims for Phase 3 (2021). It is expected that a slight modification of the formulation might give a dramatic enhancement of the drug power and in this case will govern the nature of the Phase 3. If not, the drug will still be effective for around 50% of the patient population. This de-risked clinical trial will have updated endpoints while repeating the results previously obtained in Phase 2;

The new Management by seasoned entrepreneur industrials managed to keep as close collaborators on a consulting basis the executives (CEO, CMO and CMC) who led VDA-1102's phase 2 and agreed to continue to support the team through phase 2b and phase 3 and are associated to success. A new team of executive managers is planed with time for further developments. The business opportunity resides in joining a top recognized team of experts who bought-out their company to develop promising anti-cancer skin treatment based on previously accomplished research and development ($19M invested in previous cycle including $5M from CSO). The planned exit for the investment is 2023 through M&A, IPO or partnerships.

Financing Plan

Stage 1: $5-10M now. Funding will be used to achieve a 20-30 patients Phase 2 in CTCL (Q3-4 2020) and a supplementary Phase 2B on a slightly reformulated product in AK. An extremely low burning rate is expected, due to lean structure and unnecessary local laboratories personal at this stage.

Contact Information:
Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com

Stage 2: $10-15M through investments at market value through major VCs/Pharma/IPO. Funding will be used to prepare a Phase 3 for AK and conduct a Phase 3 for CTCL as well as to explore back-up compounds & pathologies (Q1'21 – Q3'21). Co-development deal for a Phase 3 in AK.
Stage 3: Exit M&A or IPO. **Planned exit: end of 2022 - beginning of 2023.**
Investors joining ViDAC Pharma's financing plan benefit from the outcomes of $14M of research and development already invested before management buyout plus $5M of non-dilutive grants.

Timeline

2019	2020-2021	2021 - 2022	2022 - 2023
VDA-1102 Phase 2 data **Management Buyout**	Phase 2b confirmation on selective population and reformulation Phase 2 for CTCL	Phase 3 in CTCL Codev deal for AK Inflection Value Point	**Planned Exit**

Leading Team

Prof. Max Herzberg, Chairman
40 years of biotechnology industry experience, one of the founders of the Israel Biotech Industry, founder and board member of several successful biopharmaceutical companies. Inventor of the API of Vidac.
Yochai Richter PhD, Board Member
Successful entrepreneur. Chairman of Orbotech from its creation up to its $4B exit.
Christian Policard PhD, Board Member
Former Executive VP of Sanofi and VP of Institut Pasteur, Head of Biotech Life Sciences Consulting firm.
Oren Becker PhD, Board Member
Former CEO of ViDAC Pharma, 20 years of experience in the biopharmaceutical industry.

Intellectual Property

Strong patent position with several worldwide composition-of-matter and use patents (to be provided upon request). Opportunity to spin off some of the IP to develop additional ventures through incubator platforms, company to remain preferred shareholder.

Contact Information:
Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com